Tauriga Sciences Receives Notice of Allowance From the European Union Intellectual Property Office Registering its Trademark

The Company has been Granted European Union Trademark Number: 018138334

NEW YORK, NY -- February 21, 2020 -- InvestorsHub NewsWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has received a notice of allowance from the European Union Intellectual Property Office (“E.U.I.P.O.”) granting the Company its trademark registration for: Tauri-Gum™ (E.U. Trademark # 018138334). The effective registration date, granting this Tauri-Gum™ trademark to the Company, was February 18, 2020.

Below - Link to European Union Trademark Website:

https://euipo.europa.eu/eSearch/#basic/1+1+1+1/tauri-gum

The Company believes that the allowance of this European Union Trademark materially enhances the global value of its flagship brand: Tauri-Gum™. The Company continues to experience strong levels of interest from a broad array of European Distributors and will be a main floor exhibitor at the upcoming European CBD Show (“The CBD Show”) in London, United Kingdom – May 1-3, 2020.

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum™. The Company is currently in production of three distinct flavors of Tauri-Gum™: MINT, BLOOD ORANGE, and POMEGRANATE. On December 6, 2019 the Company announced that it completed the initial production run (thereby expanding its existing product lines) with the introduction of a 25mg Vegan CBD Isolate Infused vegan gummy (“gum drop”), branded under the name: Tauri-Gummies™. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com.

The Company has also announced the development of a Cannabigerol (“CBG”) Isolate infused version of Tauri-Gum™. The flavor that has been selected is Starfruit/Peach and each piece of gum will contain 10mg of CBG Isolate / Each blister pack will contain 80mg of CBG Isolate. The Company expects to commence production during its 4^thFiscal Quarter of 2020 (January 1, 2020 – March 31, 2020).

In addition, on March 11, 2019, the Company announced the official launch of its E-Commerce site - as part of its Tauri-Gum™ commercialization strategy. This site can be accessed by visiting the following URL address: www.taurigum.com

Pharmaceutical Development: On January 13, 2020, the Company announced the formation of a wholly owned subsidiary, “Tauriga Pharma Corporation,” to reflect the ongoing development of a pharmaceutical Nausea Regulation (“Anti-Nausea”) product. This proposed product has been conceived as a pharmaceutical grade version of Tauri-Gum™ (incorporating a significantly higher concentration of CBD).

CONTACT INFORMATION

Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com